NasdaqGS:BEAMBiotechs
Beam Therapeutics (BEAM) Following Ark Invest Interest And Clinical Milestones Looks Undervalued
Beam Therapeutics (BEAM) is back in focus after Ark Invest increased its position, as investors weigh upcoming clinical milestones, including a global BEAM-302 trial and a planned FDA marketing application for risto-cel.
See our latest analysis for Beam Therapeutics.
Despite Ark Invest’s increased stake and Beam Therapeutics’ upcoming clinical milestones, recent momentum has been weak, with the share price down 25.0% over 30 days and the 1-year total shareholder return still positive at...